LP
RGLS

LMR Partners’s Regulus Therapeutics RGLS Stock Holding History

LMR Partners’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,386
Closed -$164K – 504
2017
Q2 		$164K Buy
+1,386
New +$231K 0.01% 546
2014
Q2 		– Sell
-98
Closed -$106K – 540
2014
Q1 		$106K Buy
+98
New +$109K 0.01% 257

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

LMR Partners's RGLS Position: Q3 2017 in Review

LMR Partners sold out of Regulus Therapeutics (RGLS) in Q3 2017, closing a stake of 1,386 shares — an estimated $164K sold.

LMR Partners first reported a position in RGLS in Q1 2014 and held it in 2 quarters. The position peaked at $164K in Q2 2017. 48 funds tracked by Wall St. Rank hold RGLS as of Q3 2017.

  • LMR Partners reported no remaining Regulus Therapeutics position as of Q3 2017 after selling out during the quarter.
  • LMR Partners sold 1,386 Regulus Therapeutics shares in Q3 2017, an estimated $164K.
  • LMR Partners first reported a position in Regulus Therapeutics in Q1 2014 and held it in 2 quarters.
  • LMR Partners's Regulus Therapeutics position peaked at $164K in Q2 2017.
  • 48 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.